Efficacy and Safety of Olezarsen for the Management of Dyslipidemia: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Clinical Snapshot
PICO Framework
| P — Population | Patients with dyslipidemia |
| I — Intervention | Olezarsen (antisense oligonucleotide) |
| C — Comparator | Placebo |
| O — Outcomes | Lipid parameters (triglycerides, VLDL-C, apoB, non-HDL-C, apoC-III, HDL-C, LDL-C) and safety outcomes (injection site reactions, platelet counts, serious adverse events, liver enzymes) |
Bottom Line
This meta-analysis of seven RCTs (n=2,121) demonstrates that olezarsen, an antisense oligonucleotide, significantly reduces triglycerides by 59 mg/dL and improves other atherogenic lipid parameters in dyslipidemia patients. The drug shows particular efficacy in reducing triglyceride-rich lipoproteins, VLDL cholesterol, and apolipoprotein C-III while increasing HDL cholesterol, though LDL cholesterol remains unchanged. Safety concerns include increased injection site reactions (RR 3.93) and thrombocytopenia (RR 4.76), but serious adverse events were comparable to placebo. The evidence quality is moderate to low by GRADE criteria. While biochemically promising for patients with persistent hypertriglyceridemia, the authors appropriately conclude that cardiovascular outcome trials are essential before routine clinical adoption. This represents a potential therapeutic advance for high-risk patients with refractory triglyceride elevation, particularly those with familial chylomicronemia syndrome or severe hypertriglyceridemia inadequately controlled by conventional therapy.
Key Findings
P Value: Statistical significance achieved for primary lipid outcomes
Effect Size: Substantial triglyceride reduction with moderate effect on other lipid parameters
Primary Outcome: Triglyceride reduction: mean difference -59.20 mg/dL
Nnt Or Sensitivity: Risk ratio 3.93 for injection site reactions, 4.76 for thrombocytopenia
Confidence Interval: Not reported in abstract
Clinical Application
Injectable therapy requiring patient education and monitoring for injection site reactions and platelet counts Would require TGA approval and PBS listing consideration. Fits within RACGP lipid management guidelines as adjunctive therapy for high-risk patients with persistent hypertriglyceridemia despite statin therapy Patients with hypertriglyceridemia and mixed dyslipidemia requiring additional lipid-lowering therapy
Abstract
This updated systematic review and meta-analysis evaluated the efficacy and safety of olezarsen in patients with dyslipidemia. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched through September 2025 for randomized controlled trials comparing olezarsen with placebo. Seven trials (n = 2,121) were included. Olezarsen significantly reduced triglycerides (mean difference [MD] -59.20 mg/dL), very-low-density lipoprotein cholesterol (MD -52.68 mg/dL), apolipoprotein B (MD -10.74 mg/dL), non-HDL cholesterol (MD -17.06 mg/dL), and apolipoprotein C-III (MD -64.16 mg/dL), and increased HDL cholesterol (MD 30.97 mg/dL), with no significant effect on LDL cholesterol. Injection site reactions (risk ratio [RR] 3.93) and platelet counts <140,000/µL (RR 4.76) were increased, whereas serious adverse events and significant liver enzyme elevations were comparable to placebo. Certainty of evidence ranged from moderate to low. In conclusion, olezarsen produces substantial improvements in triglyceride-rich lipoproteins with an acceptable safety profile; long-term cardiovascular outcome trials are warranted.
References
- 1.Burhan, M., Ibrahim, T., Naveed, M. A., Ansari, Z., Ansab, M., Fatima, K., Ashraf, S., Shahid, Z. U. A., Raza, A., & Raza, S. H. A. (2026). Efficacy and safety of olezarsen for the management of dyslipidemia: An updated systematic review and meta-analysis of randomized controlled trials. The American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2026.03.052
Related Research
Bioelectrochemistry (Amsterdam, Netherlands)
From data to diagnosis: A comprehensive review of machine learning-driven wearable sensors in healthcare.
2 Aug 2026
Ultrasound in medicine & biology
A Systematic Review: The Application of Attention Mechanisms in Medical Ultrasound Image Processing
2 Aug 2026
Journal of the American Medical Informatics Association : JAMIA
Explainable machine learning in healthcare: methods, interpretation, and applications for clinical research
2 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service